Results 21 to 30 of about 5,019 (231)
BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
Life, 2021 Nearly four decades after their conceptualization, antibody-based therapies are slowly being added to the treatment landscape of acute myeloid leukemia (AML). While the antibody–drug conjugate gemtuzumab ozogamicin is the only antibody-based therapy that
Cecily Allen +2 more
doaj +1 more source
Bispecific T-Cell Engagers Targeting Membrane-Bound IgE [PDF]
Biomedicines, 2021 The increased incidence of allergies and asthma has sparked interest in IgE, the central player in the allergic response. Interaction with its high-affinity receptor FcεRI leads to sensitization and allergen presentation, extracellular membrane-proximal domain in membrane IgE can act as an antigen receptor on B cells, and the interaction with low ...
Aleksandra Rodak +6 more
openaire +3 more sources
Frontiers in Immunology, 2023 The activating receptor natural killer group 2, member D (NKG2D) represents an attractive target for immunotherapy as it exerts a crucial role in cancer immunosurveillance by regulating the activity of cytotoxic lymphocytes.
Sebastian Lutz +19 more
doaj +1 more source
Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy
Haematologica, 2023 T-cell-engaging bispecific antibodies (T-BsAb) have produced impressive clinical responses in patients with relapsed/refractory B-cell malignancies, although treatment failure remains a major clinical challenge. Growing evidence suggests that a complex interplay between immune cells and tumor cells is implicated in the mechanism of action and therefore,
Casey, M +7 more
openaire +6 more sources
Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia
Drugs in Context, 2020 Therapeutic options for relapsed/refractory B-cell acute lymphoblastic leukemia have evolved in the past few years. The FDA has approved three novel therapies for this disease: inotuzumab ozogamicin (an anti-CD22 antibody–drug conjugate), blinatumomab (a
Diego Conde-Royo +2 more
doaj +1 more source
Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report
JTO Clinical and Research ReportsA 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3–targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome but resulted in a
Shetal A. Patel, MD, PhD +7 more
doaj +1 more source
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
Therapeutic Advances in Medical Oncology, 2023 Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell receptor targeting a gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment.
Sarah Howlett +3 more
doaj +1 more source
A rare case of B cell lymphoblastic leukemia with inv(7)(p15q34) with review of literature.
Leukemia Research Reports, 2021 The inv(7)(p15q34) chromosomal abnormality which juxtaposes part of the HOXA gene cluster on 7p15 to the TCRβ locus on 7q34, has been described in a subset of cases of T-cell lymphoblastic leukemia, but its presence in cases of B-cell lymphoblastic ...
Bernhisel Andrew +5 more
doaj +1 more source
Biochemistry and Biophysics ReportsRecently, the development of T-cell engager cancer therapeutics, consisting of anticancer and anti-T-cell antibody parts to engage the T-cell to the cancer site, has gained interest.
Takuya Asanuma +5 more
doaj +1 more source
Molecular Therapy: Oncolytics, 2023 Adoptive cell therapy (ACT) utilizing γδ T cells is becoming a promising option for the treatment of cancer, because it offers an off-the-shelf allogeneic product that is safe, potent, and clinically effective.
Scott A. Becker +7 more
doaj +1 more source